VJOncology is committed to improving our service to you

ESMO WCGIC 2020 | KEYNOTE-966: pembrolizumab, gemcitabine and cisplatin for CCA

VJOncology is committed to improving our service to you

Arndt Vogel

Arndt Vogel, MD, Hannover Medical School, Hanover, Germany, discusses the rationale and study design of the KEYNOTE-966 trial (NCT04003636), evaluating pembrolizumab, gemcitabine and cisplatin in cholangiocarcinoma (CCA) patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter